GLP-1 Receptor Agonists

Glossary

Records checked

Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk

Qualified clinical review None on record

The 3 incretin-family receptors the corpus defines, each with a cited definition. These are the terms the compound records point at when they name a target.

Terms

GLP-1 receptor

Also written as glucagon-like peptide-1 receptor, GLP1R.

The glucagon-like peptide-1 receptor is the receptor targeted by the incretin receptor agonist class. A 2024 review in Signal Transduction and Targeted Therapy surveys its signalling mechanisms and advances in agents acting on it.[1]

Every compound in scope recorded at the GLP-1 receptor.

See also: GIP receptor, Glucagon receptor.

  1. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339

GIP receptor

Also written as glucose-dependent insulinotropic polypeptide receptor, GIPR.

The glucose-dependent insulinotropic polypeptide receptor is the second incretin receptor. Tirzepatide is reported in its 2021 Lancet trial report as a dual GIP and GLP-1 receptor agonist.[1]

Every compound in scope recorded at the GIP receptor.

See also: GLP-1 receptor.

  1. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022

Glucagon receptor

Also written as GCGR.

The glucagon receptor is the third receptor targeted by the triple agonists in this class. Retatrutide is reported in its 2023 Lancet trial report as a GIP, GLP-1 and glucagon receptor agonist.[1]

Every compound in scope recorded at the Glucagon receptor.

See also: GLP-1 receptor, GIP receptor.

  1. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (2023). pmid:37385280

Targets with no term

2 of the 5 targets recorded across the compounds in scope have no glossary entry in the corpus. Their pages say so and define nothing. The receptor index lists which.